|
市場調査レポート
商品コード
1663562
神経科市場:BCCによる調査の概要Neurology Market: A BCC Research Overview |
||||||
|
神経科市場:BCCによる調査の概要 |
出版日: 2025年02月17日
発行: BCC Research
ページ情報: 英文 185 Pages
納期: 即納可能
![]() |
世界の神経科の市場規模は、2024年の673億米ドルから、予測期間中はCAGR 7.1%で推移し、2029年には948億米ドルに達すると予測されています。
多発性硬化症の部門は、2024年の225億米ドルから、CAGR 3.9%で推移し、2029年には272億米ドルに達すると予測されています。脳腫瘍の部門は、2024年の29億米ドルから、CAGR 12.6%で推移し、2029年には53億米ドルに達すると予測されています。
当レポートでは、世界の神経科の市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、パイプラインの動向、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。
The global market for neurology is estimated to increase from $67.3 billion in 2024 to reach $94.8 billion by 2029, at a compound annual growth rate (CAGR) of 7.1% from 2024 through 2029.
The multiple sclerosis market for neurology is estimated to increase from $22.5 billion in 2024 to reach $27.2 billion by 2029, at a CAGR of 3.9% from 2024 through 2029.
The brain tumor market for neurology is estimated to increase from $2.9 billion in 2024 to reach $5.3 billion by 2029, at a CAGR of 12.6% from 2024 through 2029.
This report includes a market analysis of the therapeutics used to treat neurological conditions. The study outlines the market potential for neurology medications for both now and in the future. It also provides a thorough examination of the market's drivers, constraints, and pipeline medications, as well as the competitive landscape, laws, epidemiology of neurological disorders, mergers and acquisitions. Market forecasts through 2029 are also covered in the report.
The report breaks down neurology market shares according to various disease indications. Parkinson's disease, Alzheimer's disease, psychotic disorder, epileptic disorder, autism disorder, multiple sclerosis, brain tumor, and other diseases are the neurological disorders that make up the market segmentation. Therapeutics and regional analysis are covered in each disease segment.
Anti-Parkinson's medications are covered in the Parkinson's disease market. The market is divided into different drug classes such as dopaminergic, enzyme inhibitors, dopamine agonists and other anti-Parkinson's drugs based on drug class. Anti-Alzheimer medications are part of the Alzheimer's disease market, which is divided into segments according to respective mechanisms of action. The market is divided into two segments based on drug class: NMDA antagonists and AChE inhibitors. Antipsychotic medications are part of the market for psychotic diseases. The market is divided into different drug classes, including D2 partial agonists, D2/5HT2A antagonists, and D2 antagonists.
Anti-epileptic medications are included in the market for epileptic diseases. The market is divided into three segments based on drug class: first-generation, second-generation and third-generation. Autism spectrum disorder drugs are included in the market. Based on information on labels, the market is divided into drug categories: off-label pharmaceuticals and pharmaceuticals with an ASD label. Brain tumor treatments are included in the market for brain tumors. The market is divided into different types of therapy, such as targeted therapy and chemotherapy.
In order to provide an in-depth understanding of the market, profiles of market participants, competitive landscape, key competitors and respective market share are also part of this report. By geographical region, the market in this report is divided into four regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.